Dr. Klausner Co-Chairs Committee Preparing NAS Terrorism Report

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 3
Volume 11
Issue 3

WASHINGTON-A National Academy of Sciences (NAS) committee expects to issue a report in June on terrorism that will provide the federal government with a road map for the use of science and technology in all aspects of counterterrorism, Richard D. Klausner, MD, former National Cancer Institute (NCI) director, told ONI.

WASHINGTON—A National Academy of Sciences (NAS) committee expects to issue a report in June on terrorism that will provide the federal government with a road map for the use of science and technology in all aspects of counterterrorism, Richard D. Klausner, MD, former National Cancer Institute (NCI) director, told ONI.

Dr. Klausner and Lewis M. Branscomb, PhD, Albert Pratt Public Service Professor at Harvard University’s John F. Kennedy School of Government, co-chair the committee. About 150 outside experts and consultants are contributing to the effort, which is expected to inform the decision-making process for the fiscal year 2004 budget.

In addition to his NAS commitment, Dr. Klausner continues to pursue research part time at NCI. He resigned as director last fall after more than 6 years in the post. He originally left to head a new institute established by the Case Foundation of AOL founder Steven Case and his wife, but the Cases withdrew their commitment to the project.

Recent Videos
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content